Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06054815 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
A Phase 2 study, sponsored by NeuroBo Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT06054815 is a Phase 2 study that has completed, run by NeuroBo Pharmaceuticals. The registered enrollment target is 109 participants.
The verdict
NCT06054815, a Phase 2 study, has completed, sponsored by NeuroBo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subjects with presumed non-alcoholic steatohepatitis (NASH).
Interventions
- DRUG Sitagliptin
- DRUG DA-1241
- DRUG Sitagliptin Placebo
- DRUG DA-1241 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2024-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06054815
The ClinicalTrials.gov registry entry for NCT06054815 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeuroBo Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sitagliptin is the first listed.
NCT06054815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06054815 about?
NCT06054815 is a clinical study titled "Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH". A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subjects with presumed non-alcoholic steatohepatitis (NASH).
What is the current status of trial NCT06054815?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2023-09-14. Estimated completion is 2024-10-30.
What interventions are being tested in trial NCT06054815?
The interventions under investigation include: Sitagliptin (DRUG), DA-1241 (DRUG), Sitagliptin Placebo (DRUG), DA-1241 Placebo (DRUG).
Who is sponsoring clinical trial NCT06054815?
This trial is sponsored by NeuroBo Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.